Abstract
In humans, oxoreducing 11β-HSD-1 activity appears to be related to body fat distribution
in male-type central obesity, but not in female-type peripheral obesity. We postulated
that inhibition of 11β-HSD-1 might have clinical therapeutic significance in oxoreducing
mostly visceral fat and its metabolic activity. Our current study investigated the
consequence at the cellular level of such inhibition. As an inhibitor of 11β-HSD-1
activity, we used the licorice derivative carbenoxolone. Carbenoxolone has an inhibitory
effect on the activity of both oxidizing 11β-HSD-2, which converts cortisol to cortisone,
and oxoreducing 11β-HSD-1 [1]; yet, preadipocytes and adipocytes only express the latter. Preadipocytes were retrieved
from omental and subcutaneous fat from healthy non-obese individuals and differentiated
in vitro to mature adipocytes. Activity of 11β-HSD-1 was assayed by measuring conversion of
added 500 nM cortisone to cortisol. Expression of 11β-HSD-1 mRNA was determined by
real-time PCR, while lipolytic effects were determined by measuring glycerol and triglyceride
concentration in the culture medium. Carbenoxolone decreased 11β-HSD-1 activity in
a dose-dependent manner with an IC-50 of 5X10-6 M, but did not affect the expression of 11β-HSD-1 mRNA. Cortisone stimulated subcutaneous,
but not omental preadipocytes proliferation, an effect that was not abolished by carbenoxolone.
Dexamethasone had a stimulatory effect on the maturation of both omental and subcutaneous
preadipocytes. Carbenoxolone per se, either with or without cortisone, had a negative effect on preadipocyte maturation.
Inhibiting 11β-HSD-1 activity by carbenoxolone had no impact on leptin secretion.
Thus, carbenoxolone has no effect on preadipocyte proliferation, but a dramatic inhibitory
effect on preadipocyte differentiation into mature adipocytes. The mechanism is only
partly related to its inhibitory effect on 11β-HSD-1 activity. The present observations
lend support to the presence of an intracrine loop of a hormone that is both produced
from a precursor and active within the preadipocyte and adipocyte.
Key words
11β-HSD-1 - Carbenoxolone - Cortisone
References
- 1
Ricketts M L, Shoesmith K J, Hewison M, Strain A, Eggo M C.
Regulation of 11 β-hydroxysteroid dehydrogenase type 1 in primary cultures of rat
and human hepatocytes.
Journal of Endocrinology.
1998;
156
159-168
- 2
Masuzaki H, Paterson J, Shinyama H, Morton N M, Mullins J J, Seckl J R, Flier J S.
A transgenic model of visceral obesity and metabolic syndrome.
Science.
2001;
294
2166-2170
- 3
Stewart P M, Boulton A, Kumar S, Clark P M, Shackleton C H.
Cortisol metabolism in human obesity: impaired cortisone → cortisol conversion in
subjects with central adiposity.
J Clin Endocrinol Metab..
1999;
84
1022-1027
- 4
Tiosano D, Eisenstadt I, Militianu D, Shackleton C HL, Chrousos G P, Hochberg Z.
11β-hydroxysteroid dehydrogenase activity in hypothalamic obesity.
J Clin Endocrinol Metab.
2003;
88
385-393
- 5
Napolitano A, Voice M W, Edwards C R, Seckl J R, Chapman K E.
11Beta-hydroxysteroid dehydrogenase 1 in adipocytes: expression is differentiation-dependent
and hormonally regulated.
J Steroid Biochem Mol Biol.
1998;
64
251-260
- 6
Bujalska I J, Kumar S, Hewison M, Stewart P M.
Differentiation of adipose stromal cells: The roles of glucocorticoids and 11β-hydroxysteroid
dehydrogenase.
Endocrinology.
1999;
140
3188-3196
- 7
Ricketts M L, Shoesmith K J, Hewison M, Strain A, Eggo M C.
Regulation of 11β-hydroxysteroid dehydrogenase type 1 in primary cultures of rat and
human hepatocytes.
Journal of Endocrinology.
1998;
156
159-168
- 8
Friedberg M, Zoumakis E, Hiroi N, Bader T, Chrousos G P, Hochberg Z.
Modulation of 11β-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous
adipocytes by hypothalamic messengers.
J Clin Endocrinol Metab.
2003;
88
379-384
- 9
Bujalska I J, Walker E A, Hewison M, Stewart P M.
A switch in dehydrogenase to reductase activity of 11 beta-hydroxysteroid dehydrogenase
type 1 upon differentiation of human omental adipose stromal cells.
J Clin Endocrinol Metab.
2002;
87
1205-1210
- 10
Dembinska-Kiec A, Pallapies D, Simmet T, Peskar B M, Peskar B A.
Effect of carbenoxolone on the biological activity of nitric oxide: relation to gastroprotection.
Br J Pharmacol.
1991;
104
811-816
- 11
Nagayama S, Jono H, Suzaki H, Sakai K, Tsuruya E, Yamatsu I, Isohama Y, Miyata T,
Kai H.
Carbenoxolone, a new inducer of heat shock protein 70.
Life Sci.
2001;
69
2867-2873
- 12
Chaytor A T, Marsh W L, Hutcheson I R, Griffith T M.
Comparison of glycyrrhetinic acid isoforms and carbenoxolone as inhibitors of EDHF-type
relaxations mediated via gap junctions.
Endothelium.
2000;
7
265-278
- 13
Umezawa A, Hata J.
Expression of gap-junctional protein (connexin 43 or alpha 1 gap junction) is down-regulated
at the transcriptional level during adipocyte differentiation of H-1/A marrow stromal
cells.
Cell Struct Funct.
1992;
17
177-184
- 14
MacDougald O A, Lane M D.
Transcriptional regulation of gene expression during adipocyte differentiation.
Annu Rev Biochem.
1995;
64
345-373
- 15
Bronnegard M, Reynisdottir S, Marcus C, Stierna P, Arner P.
Effect of glucocorticosteroid treatment on glucocorticoid receptor expression in human
adipocytes.
J Clin Endocrinol Metab.
1995;
80
3608-3612
Z. Hochberg M.D., D.Sc.
Meyer Children’s Hospital
POB 9602 · Haifa 31096 · Israel ·
Fax: 972 4 8542157
Email: z_hochberg@rambam.health.gov.il